ABT-869

DRUG10 trials

Conditions

AdenocarcinomaAdenocarcinoma of the ColonAdenocarcinoma of the RectumAdvanced Colorectal CancerAdvanced Hepatocellular CarcinomaAdvanced Renal Cell CarcinomaAdvanced Solid TumorsAdvanced or Metastatic Non-Small Cell Lung Cancer

Phase 1

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

CompletedNCT00718380

AbbVieSolid Tumor

Start: 2008-09-30End: 2012-06-30Updated: 2017-11-21

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

CompletedNCT00733187

AbbVie (prior sponsor, Abbott)Advanced Solid Tumors

Start: 2009-02-28End: 2012-06-30Updated: 2017-11-21

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

WithdrawnNCT00754104

AbbottSolid Tumors

Start: 2008-09-30Updated: 2011-01-19

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)

CompletedNCT01114191

AbbottSolid Tumors

Start: 2010-05-31End: 2011-02-28Updated: 2011-07-26

Phase 2

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

CompletedNCT00486538

AbbVie (prior sponsor, Abbott)Advanced Renal Cell Carcinoma

Start: 2007-06-30End: 2012-06-30Updated: 2013-01-04

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

CompletedNCT00517920

AbbVie (prior sponsor, Abbott)Advanced Hepatocellular Carcinoma

Start: 2007-09-30End: 2012-06-30Updated: 2013-01-04

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

CompletedNCT00645177

AbbVie (prior sponsor, Abbott)Metastatic Breast Cancer

Start: 2008-07-31End: 2009-12-31Updated: 2013-01-29

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

CompletedNCT00707889

AbbVie (prior sponsor, Abbott)Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Colorectal Cancer

Start: 2008-10-31End: 2012-05-31Updated: 2013-05-15

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00716534

AbbVie (prior sponsor, Abbott)Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2008-06-30End: 2012-04-30Updated: 2013-04-29

Phase 3

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

TerminatedNCT01009593

AbbottAdenocarcinoma, Carcinoma, Carcinoma, Hepatocellular +10

Start: 2010-01-31End: 2012-07-31Updated: 2012-09-10

Related Papers

Abstract 1943: Disparities in multinational phase III liver cancer clinical trials by regions of the world